Cargando…

Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis

BACKGROUND: Platelet-to-lymphocyte ratio (PLR) has been used to predict the prognosis of patients with hepatocellular carcinoma (HCC) with inconsistent results. This meta-analysis aimed to clarify the prognostic value of PLR in patients with HCC. METHODS: We systematically retrieved relevant literat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, De-Zhao, Guo, Jia, Song, Qing-Kun, Hu, Xiang-Jin, Bao, Xu-Li, Lu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745370/
https://www.ncbi.nlm.nih.gov/pubmed/36523315
http://dx.doi.org/10.21037/tcr-22-1197
_version_ 1784849138208210944
author Li, De-Zhao
Guo, Jia
Song, Qing-Kun
Hu, Xiang-Jin
Bao, Xu-Li
Lu, Jun
author_facet Li, De-Zhao
Guo, Jia
Song, Qing-Kun
Hu, Xiang-Jin
Bao, Xu-Li
Lu, Jun
author_sort Li, De-Zhao
collection PubMed
description BACKGROUND: Platelet-to-lymphocyte ratio (PLR) has been used to predict the prognosis of patients with hepatocellular carcinoma (HCC) with inconsistent results. This meta-analysis aimed to clarify the prognostic value of PLR in patients with HCC. METHODS: We systematically retrieved relevant literature published in the PubMed, Embase, Web of Science, and Cochrane databases up to November 20, 2021. The primary outcomes were the hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS), and secondary study outcomes were recurrence-free survival (RFS), disease-free survival (DFS), progression-free survival (PFS). All statistical analyses were conducted by Review Manager 5.4.1 and STATA 16.0 software. RESULTS: A total of 21 studies comprising 8,779 patients were included in this meta-analysis. Pooled results suggested that a high PLR was significantly associated with poor OS (HR: 1.34, 95% CI: 1.18–1.52, P<0.00001; I(2)=59%, P=0.0005), RFS or DFS (HR: 1.35, 95% CI: 1.13–1.63, P=0.001; I(2)=69%, P=0.002), and PFS (HR: 1.55, 95% CI: 1.09–2.22, P=0.02; I(2)=73%, P=0.02). The subgroup analysis for OS showed, when the PLR cutoff value was greater than 150, the heterogeneity decreased to 0 (HR: 1.48, 95% CI: 1.33–1.68, P<0.00001; I(2)=0%, P=0.56); when the HBsAg positive population was increased to 100%, the heterogeneity decreased to 0 (HR: 1.46, 95% CI: 1.22–1.73, P<0.0001; I(2)=0%, P=0.45); compared with other regions in the world, it was more significant in China (HR: 1.43, 95% CI: 1.26–1.62, P<0.00001; I(2)=52%, P=0.01). In addition, scatter plot showed that the HR was negatively correlated with the proportion of patients with liver cirrhosis. CONCLUSIONS: This meta-analysis suggests that PLR is a negative correlation prognostic biomarker for HCC, high PLR values indicate poor OS, RFS, DFS and PFS, especially in hepatitis B virus (HBV) related patients.
format Online
Article
Text
id pubmed-9745370
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-97453702022-12-14 Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis Li, De-Zhao Guo, Jia Song, Qing-Kun Hu, Xiang-Jin Bao, Xu-Li Lu, Jun Transl Cancer Res Original Article BACKGROUND: Platelet-to-lymphocyte ratio (PLR) has been used to predict the prognosis of patients with hepatocellular carcinoma (HCC) with inconsistent results. This meta-analysis aimed to clarify the prognostic value of PLR in patients with HCC. METHODS: We systematically retrieved relevant literature published in the PubMed, Embase, Web of Science, and Cochrane databases up to November 20, 2021. The primary outcomes were the hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS), and secondary study outcomes were recurrence-free survival (RFS), disease-free survival (DFS), progression-free survival (PFS). All statistical analyses were conducted by Review Manager 5.4.1 and STATA 16.0 software. RESULTS: A total of 21 studies comprising 8,779 patients were included in this meta-analysis. Pooled results suggested that a high PLR was significantly associated with poor OS (HR: 1.34, 95% CI: 1.18–1.52, P<0.00001; I(2)=59%, P=0.0005), RFS or DFS (HR: 1.35, 95% CI: 1.13–1.63, P=0.001; I(2)=69%, P=0.002), and PFS (HR: 1.55, 95% CI: 1.09–2.22, P=0.02; I(2)=73%, P=0.02). The subgroup analysis for OS showed, when the PLR cutoff value was greater than 150, the heterogeneity decreased to 0 (HR: 1.48, 95% CI: 1.33–1.68, P<0.00001; I(2)=0%, P=0.56); when the HBsAg positive population was increased to 100%, the heterogeneity decreased to 0 (HR: 1.46, 95% CI: 1.22–1.73, P<0.0001; I(2)=0%, P=0.45); compared with other regions in the world, it was more significant in China (HR: 1.43, 95% CI: 1.26–1.62, P<0.00001; I(2)=52%, P=0.01). In addition, scatter plot showed that the HR was negatively correlated with the proportion of patients with liver cirrhosis. CONCLUSIONS: This meta-analysis suggests that PLR is a negative correlation prognostic biomarker for HCC, high PLR values indicate poor OS, RFS, DFS and PFS, especially in hepatitis B virus (HBV) related patients. AME Publishing Company 2022-11 /pmc/articles/PMC9745370/ /pubmed/36523315 http://dx.doi.org/10.21037/tcr-22-1197 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Li, De-Zhao
Guo, Jia
Song, Qing-Kun
Hu, Xiang-Jin
Bao, Xu-Li
Lu, Jun
Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis
title Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis
title_full Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis
title_fullStr Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis
title_full_unstemmed Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis
title_short Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis
title_sort prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745370/
https://www.ncbi.nlm.nih.gov/pubmed/36523315
http://dx.doi.org/10.21037/tcr-22-1197
work_keys_str_mv AT lidezhao prognosticpredictionoftheplatelettolymphocyteratioinhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT guojia prognosticpredictionoftheplatelettolymphocyteratioinhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT songqingkun prognosticpredictionoftheplatelettolymphocyteratioinhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT huxiangjin prognosticpredictionoftheplatelettolymphocyteratioinhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT baoxuli prognosticpredictionoftheplatelettolymphocyteratioinhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT lujun prognosticpredictionoftheplatelettolymphocyteratioinhepatocellularcarcinomaasystematicreviewandmetaanalysis